SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlanzapine is an established antiemetic for the prevention of chemotherapy-induced nausea and vomiting (CINV), although the optimal dose for balancing efficacy and tolerability remains uncertain. We conducted a systematic review and network meta-analysis comparing olanzapine 2.5 mg, 5 mg, and 10 mg for CINV prophylaxis.
methodsPubMed, Embase, and Cochrane CENTRAL were searched from inception to April 9, 2026 for randomized controlled trials evaluating olanzapine for CINV prophylaxis in adults receiving chemotherapy. A frequentist random-effects network meta-analysis was performed. Primary outcomes included complete response during the acute, delayed, long-delayed, and overall phases. Secondary outcomes included complete control, no nausea, no vomiting, and safety outcomes.
resultsA total of 54 randomized controlled trials involving 10,455 participants were included. Olanzapine-containing regimens consistently improved complete response, complete control, no nausea, and no vomiting outcomes compared with placebo-controlled regimens across all phases of CINV. Olanzapine 10 mg generally demonstrated the numerically largest efficacy estimates. However, direct comparisons between olanzapine 10 mg and 5 mg did not demonstrate statistically significant differences across efficacy outcomes, suggesting preserved efficacy with dose reduction. In highly emetogenic chemotherapy populations, olanzapine 5 mg demonstrated efficacy comparable to olanzapine 10 mg. In moderately emetogenic chemotherapy populations, olanzapine 5 mg consistently improved outcomes compared with placebo-controlled regimens. Dose reduction from olanzapine 10 mg to 5 mg was not clearly associated with lower sedation risk. Evidence for olanzapine 2.5 mg remained very limited but suggested the possibility of preserved efficacy with lower toxicity.
conclusionsOlanzapine-containing regimens significantly improved prevention of CINV. Olanzapine 5 mg appeared to preserve substantial efficacy relative to olanzapine 10 mg, although dose reduction did not clearly reduce sedation risk. Additional randomized trials are needed to further define the optimal olanzapine dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.